54904-23-3

Basic information

• Product Name: 3-(5-BROMO-1H-INDOL-3-YL)-PROPIONIC ACID
• Synonyms: 5-BROMOINDOLE-3-PROPIONIC ACID;5-BROMO-INDOL-3-PROPIONIC ACID;3-(5-BROMO-1H-INDOL-3-YL)-PROPIONIC ACID;3-(5-bromo-1h-indol-3-yl)propanoic acid;5-Bromo-1H-indole-3-propanoic acid;1H-Indole-3-propanoic acid, 5-bromo-
• CAS NO: 54904-23-3
• Molecular Formula: C11H10BrNO2
• Molecular Weight: 268.11
• Product Categories: Aromatic Propionic Acids;Carboxylic Acids;Pyrroles & Indoles;Carboxylic Acids;Pyrroles & Indoles
• Mol File: 54904-23-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 467.5 °C at 760 mmHg
• Flash Point: 236.5 °C
• Appearance: /
• Density: 1.654 g/cm³
• Vapor Pressure: 1.54E-09mmHg at 25°C
• Refractive Index: 1.69
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 3-(5-BROMO-1H-INDOL-3-YL)-PROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(5-BROMO-1H-INDOL-3-YL)-PROPIONIC ACID(54904-23-3)
• EPA Substance Registry System: 3-(5-BROMO-1H-INDOL-3-YL)-PROPIONIC ACID(54904-23-3)

Safety Data

• Hazardous Substances Data: 54904-23-3(Hazardous Substances Data)

Usage

General Description

3-(5-Bromo-1H-indol-3-yl)-propionic acid is a chemical compound with the molecular formula C11H10BrNO2. It is a derivative of indole, a heterocyclic aromatic organic compound. 3-(5-BROMO-1H-INDOL-3-YL)-PROPIONIC ACID consists of a propionic acid group attached to an indole ring that has a bromine substituent at the 5-position. The presence of the bromine atom makes it a halogenated compound. This chemical may be used in pharmaceutical research or as a precursor to other organic compounds. It is important to handle this compound with appropriate care, as it may have specific hazards associated with its handling and use.

InChI:InChI=1/C11H10BrNO2/c12-8-2-3-10-9(5-8)7(6-13-10)1-4-11(14)15/h2-3,5-6,13H,1,4H2,(H,14,15)

Upstream product

• 10075-50-0 5-bromo-1H-indole 
• 79-10-7 acrylic acid 

Relevant articles and documents

TETRAHYDROISOQUINOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF

Disclosed are a novel tetrahydroisoquinoline compound, a method for preparing intermediates thereof, a pharmaceutical composition thereof and the use thereof. The tetrahydroisoquinoline compound of the present invention has a good inhibitory effect on phosphodiesterase (PDE4), and can be used in the prevention, treatment or auxiliary treatment of multiple diseases associated with the activity or expression of phosphodiesterase, especially PDE4-associated immune and inflammatory diseases, such as psoriasis and arthritis. (I)

Indole-derived psammaplin a analogues as epigenetic modulators with multiple inhibitory activities

A SAR study has been carried out around a modified scaffold of the natural product psammaplin A obtained by replacing the o-bromophenol unit by an indole ring. A series of indole psammaplin A constructs were generated in a short synthetic sequence that starts with the functionalization of the C3 indole position with in situ generated nitrosoacrylate, and this is followed by protection of the β-indole-α-oximinoesters, saponification, condensation with symmetrical diamines, and deprotection. Biochemical and cellular characterization using U937 and MCF-7 cells confirmed that many of these analogues displayed more potent actitivies than the parent natural product. Moreover, in addition to the reported HDAC and DNMT dual epigenetic inhibitory profile of the parent compound, some analogues, notably 4a (UVI5008), also inhibited the NAD+-dependent SIRT deacetylase enzymes. The SAR study provides structural insights into the mechanism of action of these multiple epigenetic ligands and paves the way for additional structural exploration to optimize their pharmacological profiles. Because of their multi(epi)target features and their action in ex vivo samples, the indole-based psammaplin A derivatives are attractive molecules for the modulation of epigenetic disorders.

PPAR active compounds

Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.